A retrospective analysis of 140 dogs with oral melanoma treated with external beam radiation

Veterinary Radiology and Ultrasound

Volumn 44, Issue 3, 2003, Pages 352-359

  Proulx, David R ^a   Ruslander, David M ^a   Dodge, Richard K ^b   Hauck, Marlene L ^a   Williams, Laurel E ^a   Horn, Birgitte ^c   Price, G Sylvester ^d   Thrall, Donald E ^a  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

^b DUKE CANCER INSTITUTE   (United States)

^c Bundoora Veterinary Hospital   (Australia)

^d ETHICON INC   (United States)

Author keywords

Dog; Oral malignant melanoma; Prognostic factors; Radiation therapy

Indexed keywords

CANIS FAMILIARIS;

ANIMAL; ANIMAL DISEASE; ARTICLE; DISEASE FREE SURVIVAL; DOG; DOG DISEASE; FEMALE; INFORMATION PROCESSING; MALE; MELANOMA; MORTALITY; MOUTH TUMOR; RADIATION DOSE FRACTIONATION; RETROSPECTIVE STUDY; SURVIVAL; TREATMENT OUTCOME; TUMOR RECURRENCE; UNITED STATES;

ANIMALS; DISEASE-FREE SURVIVAL; DOG DISEASES; DOGS; DOSE FRACTIONATION; FEMALE; MALE; MELANOMA; MOUTH NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; NORTH CAROLINA; RECORDS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0038486704     PISSN: 10588183     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1740-8261.2003.tb00468.x     Document Type: Article

References (46)

1. Brodey RS. A clinical and pathological study of 130 neoplasms of the mouth and pharynx in the dog. Am J Vet Res 1980;21:787-812.
2. Todoroff RJ, Brodey RS. Oral and pharyngeal neoplasia in the dog: a retrospective survey of 361 cases. J Am Vet Med Assoc 1979;175(6):567-571.
3. Withrow SJ. Cancer of the oral cavity. In: Withrow SJ, MacEwen EG (eds): Small Animal Clinical Oncology. Philadelphia, WB Saunders Co. 2001, pp 305-318.
4. Hoyt RF, Withrow SJ. Oral malignancy in the dog. J Am Anim Hosp Assoc 1984;20:83-92.
5. Theilen GH, Madewell BR. Cancer of the gastrointestinal tract. In: Theilen GH, Madewell BR (eds): Veterinary Cancer Medicine. Philadelphia, Lea & Febiger, 1979, pp 307-331.
6. Bostock DE. Prognosis after surgical excision of canine melanomas. Vet Pathol 1979;16(1):32-40.
7. Frese K. Developmental studies on melanoma of the skin and mouth mucosa of dogs. Vet Pathol 1978;15(4):461-473.
8. Kosovsky JK, Matthiesen DT, Marretta SM, Patnaik AK. Results of partial mandibulectomy for the treatment of oral tumors in 142 dogs. Vet Surg 1991;20(6):397-401.
9. Wallace J, Matthiesen DT, Patnaik AK. Hemimaxillectomy for the treatment of oral tumors in 69 dogs. Vet Surg 1992;21(5):337-341.
10. Konefal JB, Emami B, Pilepich MV. Malignant melanoma: analysis of dose fractionation in radiation therapy. Radiology 1987;164(3):607-610.
11. Hornsey S. The relationship between total dose, number of fractions, and fractions size in the response of malignant melanoma in patients. Br J Radiol 1978;51(11):905-909.
12. Overgaard J. The role of radiotherapy in recurrent and metastatic malignant melanoma: a clinical radiobiological study. Int J Radiat Oncol Biol Phys 1986;12(6):867-872.
13. Rofstad EK. Radiation biology of malignant melanoma. Acta Radiol 1986;25:1-10.
14. Dewey DL. The radiosensitivity of melanoma cells in culture. Br J Radiol 1971;44:816-817.
15. Barranco SC, Romsdahl MM, Humphrey RM. The radiation response of human malignant melanoma cells grown in vitro. Cancer Res 1971;31:830-833.
16. Hornsey S. The radiation response of human malignant melanoma cells in vitro and in vivo. Cancer Res 1972;32(3):650-651.
17. Bentzen SM, Overgaard J, Thames HD, Overgaard M, Vejby Hansen P, von der Maase H, et al. Clinical radiobiology of malignant melanoma. Radiother Oncol 1989;16(3):169-182.
18. Overgaard J, Overgaard M, Hansen PV, von der Maase H. Some factors of importance in the radiation treatment of malignant melanoma. Radiother Oncol 1986;5(3):183-192.
19. Bateman KE, Catton PA, Pennock PW, Kruth SA. 0-7-21 radiation therapy for the treatment of canine oral melanoma. J Vet Intern Med 1994;8(4):267-272.
20. Blackwood L, Dobson MA. Radiotherapy of malignant melanomas in dogs. J Am Vet Med Assoc 1996;209(1):98-102.
21. Theon AP, Rodriguez C, Madewell BR. Analysis of prognostic factors and patterns of failure in dogs with malignant oral tumors treated with megavoltage irradiation. J Am Vet Med Assoc 1997;210(6):778-784.
22. Casper ES, Bajorin D. Phase II trial of carboplatin in patients with advanced melanoma. Invest New Drugs 1990;8(2):187-190.
23. Chang A, Hunt M, Parkinson DR, Hochster H, Smith TJ. Phase II trial of carboplatin in patients with metastatic malignant melanoma: a report from the Eastern Cooperative Oncology Group. Am J Clin Oncol 1993;16(2):152-155.
24. Evans LM, Casper ES, Rosenbluth R. Phase II trial of carboplatin in advanced malignant melanoma. Cancer Treat Rep 1987;71(2):171-172.
25. Serrone L, Zeuli M, Sega FM, Cognetti F. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res 2000;19(1):21-34.
26. Page RL, Thrall DE, Dewhirst MW, Macy DW, George SL, McEntee MC, et al. Phase I study of melphalan alone and melphalan plus whole body hyperthermia in dogs with malignant melanoma. Int J Hyperthermia 1991;7(4):559-566.
27. Rassnick KM, Ruslander DM, Cotter SM, Al-Sarraf R, Bruyette DS, Gamblin RM, et al. Use of carboplatin for treatment of dogs with malignant melanoma: 27 cases (1989-2000). JAVMA 2001;218(9):1444-1448.
28. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Amer Stat Assoc 1958;53:457-481.
29. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer 1977;35:1-39.
30. Kobayashi T, Hauck ML, Dodge R, Page RL, Price S, Williams LE, et al. Preoperative radiotherapy for vaccine associated sarcoma in 92 cats. Vet Radiol Ultrasound 2002;43:473-479.
31. Cox DR. Regression models and life tables. J R Stat Soc B 1972;34:187-202.
32. Armitage P. Statistical Methods in Medical Research. London, Blackwell Scientific, 1987, pp 371-407.
33. Hosmer DW, Lemeshow S. Applied logistic regression. New York, Wiley, 1989, pp 25-34.
34. Konefal JB, Emami B, Pilepich MV. Analysis of dose fractionation in the palliation of metastases from malignant melanoma. Cancer 1988;61(2):243-246.
35. Lobo PA, Liebner EJ, Chao JJ, Kanji AM. Radiotherapy in the management of malignant melanoma. Int J Radiat Oncol Biol Phys 1981;7(1):21-26.
36. Ziegler JC, Cooper JS. Brain metastases from malignant melanoma: conventional vs. high-dose-per-fraction radiotherapy. Int J Radiat Oncol Biol Phys 1986;12(10):1839-1842.
37. Sause WT, Cooper JS, Rush S, Ago CT, Cosmatos D, Coughlin CT, et al. Fraction size in external beam radiation therapy in the treatment of melanoma. Int J Radiat Oncol Biol Phys 1991;20(3):429-432.
38. Rofstad EK. Fractionation sensitivity (alpha/beta ratio) of human melanoma xenografts. Radiother Oncol 1994;33(2):133-138.
39. Rofstad EK. Influence of cellular radiation sensitivity on local tumor control of human melanoma xenografts given fractionated radiation treatment. Cancer Res 1991;51(17):4609-4612.
40. Hahn KA, DeNicola DB, Richardson RC. Canine oral malignant melanoma: prognostic utility of an alternative staging system. J Small Anim Pract 1994;35:251-256.
41. Ang KK, Peters LJ, Weber RS, Morrison WH, Frankenthaler RA, Garden AS, et al. Postoperative radiotherapy for cutaneous melanoma of the head and neck region. Int J Radiat Oncol Biol Phys 1994;30(4):795-798.
42. Gillgren P, Mansson-Brahme E, Frisell J, Johansson H, Larsson O, Ringborg U. A prospective population-based study of cutaneous malignant melanoma of the head and neck. Laryngoscope 2000;110(9):1498-1504.
43. Mitchell MS. Perspective on allogeneic melanoma lysates in active specific immunotherapy. Semin Oncol 1998;25(6):623-635.
44. Morton DL, Foshag LJ, Hoon DS, Nizze JA, Famatiga E, Wanek LA, et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 1992;216(4):463-482.
45. Park JH, Kim CJ, Lee JH, Shin SH, Chung GH, Jang YS. Effective immunotherapy of cancer by DNA vaccination. Mol Cells 1999;9(4):384-391.
46. Steitz J, Bruck J, Steinbrink K, Enk A, Knop J, Tuting T. Genetic immunization of mice with human tyrosinase-related protein 2: implications for the immunotherapy of melanoma. Int J Cancer 2000;86(1):89-94.